IC14 – an investigational anti-CD14 monoclonal antibody for COVID-19 and ALS

Via a unique molecular target
and a first-in-class biologic,
starting with ALS/MND and COVID-19 ARDS

Implicit Bioscience is committed to advancing transformative therapies to impact life-threatening diseases 
IC14 will enter proof-of-concept phase 2 study in the USA in 2020 in two diseases that are poorly treated
IC14 – our lead therapeutic candidate – regulates pathogenic inflammatory responses to infection and injury
We are pleased to partner with leading agencies, investigators & companies to accelerate IC14 development

Doctor viewing brain scans

IC14 Clinical Trials


IC14 (Anti-CD14) in Patients With SARS-CoV-2 (COVID-19)

A multicenter, randomized, double-blind, placebo-controlled phase 2 study of IC14, an antibody to CD14, in reducing the severity of respiratory disease in hospitalized COVID-19 patients.

More info: NCT04391309, ClinicalTrials.gov


IC14 has been selected for inclusion in a platform phase 2 clinical study by the Healey Center at Massachusetts General Hospital

This perpetual, multi-center, multi-regimen phase 2b clinical trial will evaluate the safety and efficacy of investigational products for the treatment of ALS.

Information release from the Healey Center: https://www.massgeneral.org/neurology/als/research/first-platform-trial-treatments

A world-class team

The Implicit Bioscience team includes global
leaders in neuroscience and immunology